Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Elevation in serum troponin I predicts the benefit of tirofiban
Autore:
Januzzi, JL; Chae, CU; Sabatine, MS; Jang, IK;
Indirizzi:
Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med, Boston, MA USA Harvard Univ Boston MA USA sachusetts Gen Hosp, Dept Med, Boston, MA USA Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA 02114 USA Harvard Univ Boston MA USA 02114 h Med, Div Cardiol, Boston, MA 02114 USA
Titolo Testata:
JOURNAL OF THROMBOSIS AND THROMBOLYSIS
fascicolo: 3, volume: 11, anno: 2001,
pagine: 211 - 215
SICI:
0929-5305(200105)11:3<211:EISTIP>2.0.ZU;2-A
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACUTE CORONARY SYNDROMES; REFRACTORY UNSTABLE ANGINA; WAVE MYOCARDIAL-INFARCTION; INTRACORONARY THROMBUS; PRISM-PLUS; T LEVELS; RISK; STRATIFICATION; DEATH;
Keywords:
acute coronary syndromes; glycoprotein IIb/IIIa inhibitor; troponins;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
19
Recensione:
Indirizzi per estratti:
Indirizzo: Jang, IK Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Bulfinch 105,55 Fruit St, Boston, MA 02114 USA Harvard Univ Bulfinch 105,55 Fruit St Boston MA USA 02114 114 USA
Citazione:
J.L. Januzzi et al., "Elevation in serum troponin I predicts the benefit of tirofiban", J THROMB TH, 11(3), 2001, pp. 211-215

Abstract

Background: Elevations in serum troponins among patients with acute coronary syndromes have been shown to identify those patients who are at high risk for poor outcome and who accrue larger relative benefits from aggressive antiplatelet and antithrombotic therapies. We studied a group of patients from the PRISM-PLUS trial to explore whether simply using serum troponin I, a serum marker of cardiac injury, could predict benefit of GP IIb/IIIa receptor antagonism with tirofiban. Methods and Results: For this study, the subjects consisted of 55 patientsreceiving the combination therapy of tirofiban/heparin, and 55 receiving heparin alone. The baseline characteristics were similar between the two treatment groups. Serial blood samples were obtained over the first 24-hour period following randomization to study drug, and were analyzed for troponin I (TnI) levels. Among those patients with elevated serum TnI (>0.5 ng/ml), the 30-day event rate for death or myocardial infarction (MI) was reduced from 20.6% among the heparin only group to 3.6% for those treated with the combination of tirofiban/heparin, an absolute risk reduction of 17% and relative risk reduction of 83% (p=0.06). Among the TnI negative patients, the rates of death/MI at 30 days were 9.5% and 11.1% among the combination and heparin treated groups respectively (p=NS). Conclusion: Irrespective of high-risk clinical factors, including ST segment depression, these data support the hypothesis that serum troponins identify those who benefit from aggressive antiplatelet therapy with tirofiban.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 14/07/20 alle ore 19:10:14